1. Scrip
  2. >>Focus On Asia
  3. >>China

Dance With Domestic Companies: Pfizer And Merck Look To Broaden Market Access In China Via JVs

 
• By Jialing Dai

Merck/Simcere, Pfizer/Hisun launched JVs in China this week to increase sales in outlying cities.

SHANGHAI – After watching several rounds of price cuts on branded generics, which account for roughly 80% of multinational companies’ business in China, Merck & Co. Inc. and Pfizer Inc. hope to boost volume of off-patent products via partnerships with local companies. First, Merck and Simcere Pharmaceutical Group officially launched a joint venture in Shanghai Sept. 12, and the following day, Pfizer announced the launch of its JV with Zhejiang Hisun Pharmaceutical Co. Ltd.

Both moves should be seen in the greater context of China healthcare reforms, including the expansion of basic health insurance to virtually all of China’s 1.3 billion people

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Focus On Asia